Type 2

CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies….1 hour ago

News Source0177 views

CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies….1 hour ago

Related posts

WVU Medicine endocrinologist highlights steps to prevent and manage diabetes

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Dexcom unveils Type 2 diabetes CGM data at ATTD